Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Fig. 2

Response rate of MM patients based on CAF levels. The blood levels of CAFs significantly correlate with MM response to therapy. Lower levels of ANG-2 (p < 0.05), FGF-2 (p < 0.005), HGF (p < 0.05), IL-8 (p < 0.05), PDGF-BB (p < 0.005), TNF-α (p < 0.05), and VEGF (p < 0.005) are indicative of more profound response, VGPR or better, in all patients, with no evident differences between the two therapy regimens (VMPT-VT vs VMP: p = 0.1)

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us